B O O K - American College of Rheumatology

ACR Poster Session A
142. The Intra- and Inter-Reader Reliability of the Oslo Hand
Osteoarthritis (HOA) Magnetic Resonance Imaging (MRI)
Score. Ida Kristin Haugen 2 , Siri Lillegraven 2 , Barbara Slatkowsky-
Christensen 2 , Espen Haavardsholm 2 , Sølve Sesseng 2 , Tore K.
Kvien 1 , Desiree M. Van Der Heijde 3 and Pernille Bøyesen 2 ,
1
Diakonhjemmet Hospital, Oslo, Norway, 2 Diakonhjemmet
Hospital, 3 Leiden University Medical Center, Meerssen, The
Netherlands.
143. Validity and Responsiveness to Change of Radiograph-Based
Joint Space Narrowing Metric Measurement: A Systematic
Review. Delphine Chu Miow Lin 6 , William M. Reichmann 2 , Laure
Gossec 4 , Elena Losina 1 , Philip G. Conaghan 5 and Jean-Francis
Maillefert 3 , 1 Department of Orthopaedic Surgery, Brigham and
Women’s Hospital, Boston, MA, 2 Department of Orthopaedic
Surgery, Brigham and Women’s Hospital, Boston, MA and
3
. Department of Biostatistics, Boston University School of
Public Health, Boston, MA, 3 Department of Rheumatology,
Dijon University Hospital, Dijon, F-21078, France, University
of Burgundy, Dijon, F-21079, France, INSERM U887, Dijon,
F-21079, France, 4 Paris Descartes University, Medicine Faculty;
UPRES-EA 4058; APHP, Rheumatology B Department, Cochin
Hospital, Paris France, 5 Section of Musculoskeletal Disease,
University of Leeds & NIHR Leeds Musculoskeletal Biomedical
Research Unit, Leeds, UK, 6 Tours Medicine Faculty; Department
of Rheumatology, Tours University Hospital, Tours, France.
Metabolic and Crystal Arthropathies - Therapeutics and Outcomes
I
144. A Single Cohort, Dose Escalation Phase 1 Study of Intravenous
Infusion of Pegsiticase (Formerly Uricase-PEG 20), a Drug for
Managing Hyperuricemia in Refractory Gout. Tony Fiorino 3 ,
Alan J. Kivitz 1 , Patricia Pardo 5 , Rocelle Flores 2 , Zhihua Zhang 2 and
John S. Bomalaski 4 , 1 Altoona Arthritis & Osteo Ctr, Duncansville,
PA, 2 EnzymeRx, 3 EnzymeRx, Paramus, NJ, 4 EnzymeRx, Wayne,
PA, 5 Miami Research Associates, Miami, FL.
145. Canakinumab (ACZ885) Relieves Pain and Controls
Inflammation Rapidly in Patients with Difficult-To-Treat Gouty
Arthritis: Comparison with Triamcinolone Acetonide. A. So 6 ,
M. De Meulemeester 4 , A. Pikhlak 2 , A. E. Yücel 1 , U. Arulmani 3 , D.
Richard 3 , V. Murphy 3 , P. Sallstig 3 and N. Schlesinger 5 , 1 Baskent
University, Ankara, Turkey, 2 Moscow State University of
Medicine and Dentistry, Moscow, Russian Federation, 3 Novartis
Pharma AG, Basel, Switzerland, 4 Private Practice, Gozée,
Belgium, 5 UMDNJ-Robert Wood Johnson Medical School, New
Brunswick, NJ, 6 University of Lausanne, Lausanne, Switzerland.
146. Change in Uric Acid Level Is Associated with Change in Patient
Reported Outcomes in the Context of a Clinical Trial for
Chronic Gout. Will Taylor 1 , Steve Hamburger 2 , Lisa K. Stamp 5 ,
Zebulun D. Horowitz 3 and Nicola Dalbeth 4 , 1 Department of
Medicine, University of Otago Christchurch, New Zealand,
2
Savient Pharmaceuticals, Inc., E. Brunswick NJ, 3 Savient
Pharmaceuticals, Inc., E. Brunswick NJ, Baskingridge, NJ,
4
Univ Auckland, Auckland, New Zealand, 5 University of Otago
Christchurch, Christchurch, New Zealand.
147. Chronologic Age, Renal Function, and Comorbid Conditions
(Physiologic Age) of Patients with Gout Did Not Increase
Likelihood of Adverse Events (AEs): AGREE Study Post Hoc
Analyses. Daniel E. Furst 1 , Paul Maranian 1 , Matthew W. Davis 3 ,
Suman Wason 3 , Dinesh Khanna 1 and Robert Terkeltaub 2 ,
1
University of California Los Angeles, Los Angeles, CA,
2
University of California San Diego, San Diego, CA, 3 URL Pharma,
Inc, Philadelphia, PA.
148. Colchicine Use Is Associated with Decreased Diagnosis of
Myocardial Infarction (MI) and Trend toward Reduction of All-
Cause Mortality and C-Reactive Protein (CRP) Levels: Insights
from the NY VA Gout Cohort. Aaron Lehmann 5 , Laura Schneck 5 ,
Robert T. Keenan 2 , William O’Brien 6 , Daria B. Crittenden 6 , Kristen
Lee 6 , Rekha Tadoori 6 , Jeffrey D. Greenberg 1 , Bruce N. Cronstein 3 ,
Steven Sedlis 4 and Michael H. Pillinger 5 , 1 Millburn, NJ, 2 Duke
University, Durham, NC, 3 New York Univ Med Ctr, New York, NY,
4
NYU Langone Medical Center, 5 NYU Langone Medical Center,
NYU Hospital for Joint Diseases, New York, NY, 6 NYU Langone
Medical Center, NYU Hospital for Joint Diseases.
149. Effect of Multiple Doses of Febuxostat on the
Pharmacokinetics of a Single Dose of Theophylline. Max Tsai,
Jingtao Wu, Lhanoo Gunawardhana and Himanshu Naik, Takeda
Global Research &Development Center, Inc., Deerfield, IL.
150. Effects of a Purine Nucleoside Phosphorylase Inhibitor,
BCX4208, on the Serum Uric Acid Concentrations in Patients
with Gout. David Fitz-Patrick 2 , Waymon Drummond 4 , John
Pappas 3 and Alan S. Hollister 1 , 1 BioCryst Pharmaceuticals,
Inc., Durham, NC, 2 East-West Medical Research Institute,
Honolulu, HI, 3 Kentucky Medical Research Center, Lexington, KY,
4
Renaissance Clinical Research, Dallas, TX.
151. Efficacy and Tolerability of Celecoxib in the Treatment
of Moderate to Extreme Pain Associated with Acute
Gouty Arthritis: A Randomized Controlled Trial. H. Ralph
Schumacher 4 , Manuela Berger 3 , Julie Li-Yu 5 , Fernando Perez-
Ruiz 1 , Ruben Burgos Vargas 2 and Chunming (Mark) Li 3 , 1 Hospital
de Cruces, Baracaldo, Spain, 2 Hospital General de México,
México City, Mexico, 3 Pfizer Inc., New York, NY, 4 University of
Pennsylvania VA Medical Center, Philadelphia, PA, 5 University of
Santo Tomas Hospital, Manila, Philippines.
152. Evaluation of Rilonacept for Prevention of Gout Flares during
Initiation of Urate-Lowering Therapy: Results of a Phase 3,
Randomized, Double-Blind, Placebo-Controlled Trial. Robert
Terkeltaub 6 , H. Ralph Schumacher 5 , Kenneth G. Saag 4 , James
Clower 7 , William Jennings 1 , Robert R. Evans 2 , Jian Wang 3 ,
Shirletta King-Davis 3 and Steven P. Weinstein 2 , 1 Radiant
Research, San Antonio, TX, 2 Regeneron Pharmaceuticals, Inc.,
Tarrytown, NY, 3 Regeneron Pharmaceuticals, Inc., 4 University
of Alabama-Birmingham, Birmingham, AL, 5 VA Medical Center
and UPenn, Philadelphia, PA, 6 VA Medical Ctr, San Diego, CA,
7
Westside Center for Clinical Research, Jacksonville, FL.
153. Evaluation of Rilonacept in Patients with Gouty Arthritis
Experiencing an Acute Gout Attack. Robert Terkeltaub 6 , H.
Ralph Schumacher 5 , Craig Curtis 1 , Neil Patterson 2 , Robert
R. Evans 3 , Jian Wang 4 , Shirletta King-Davis 4 and Steven P.
Weinstein 3 , 1 Compass Research, Orlando, FL, 2 Private Practice,
Oviedo, FL, 3 Regeneron Pharmaceuticals, Inc., Tarrytown,
NY, 4 Regeneron Pharmaceuticals, Inc., 5 VA Medical Center,
Philadelphia, PA, 6 VA Medical Ctr, San Diego, CA.
154. Febuxostat Versus Allopurinol in the Treatment of Gout
in Subjects >65 Years of Age: A Subgroup Analysis of the
CONFIRMS Trial. Eswar Krishnan 1 , Patricia A. MacDonald 2 ,
Barbara Hunt 2 and Robert Jackson 2 , 1 Stanford University,
Stanford, CA, 2 Takeda Global Research & Development Center,
Inc., Lake Forest, IL.
155. Healthcare Utilization and Productivity at Home and Work
Place in Tophaceous vs. Non-Tophaceous Gout. Puja Khanna 3 ,
Jay Persselin 1 , Ron Hays 2 , Daniel Furst 2 , Harold Paulus 2 , Paul
Maranian 2 and Dinesh Khanna 2 , 1 Greater Los Angeles VA, 2 UCLA,
3
UCLA and Greater Los Angeles VA.
2010 Program Book 157